|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
La Jolla Pharmaceutical Co (LJPC) |
|
|
$6.22 0.00 (0.00%) as of 4:30 Thu 8/18
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
27,470,000 |
| Market
Cap: |
170.86(M) |
| Last
Volume: |
2,592,323 |
Avg
Vol: |
2,568,054 |
| 52
Week Range: |
$6.22 - $6.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jenn Paul |
VP of Product Development |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$512 |
D/D |
361 |
2,568 |
|
- |
|
| Welch William J |
VP Sales & Marketing |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$635 |
D/D |
447 |
1,909 |
|
- |
|
| Sloan Gail A |
VP of Finance |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$460 |
D/D |
324 |
13,300 |
|
- |
|
| Heilbrunn Kenneth R |
VP of Clinical Development |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$786 |
D/D |
554 |
11,028 |
|
- |
|
| Reilly Teddi |
VP of Human Resources |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$2,409 |
D/D |
1,697 |
22,131 |
|
- |
|
| Bennett Bruce K Jr |
VP of Manufacturing |
• – – |
2004-12-31 |
5 |
A |
$1.42 |
$547 |
D/D |
385 |
37,495 |
|
- |
|
| Elchico Josefina T |
Vice President Quality SystemO |
• – – |
2004-10-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
- |
|
| Wiseman Andrew |
Sen Dir Investor Relations |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$385 |
D/D |
260 |
17,625 |
|
- |
|
| Linnik Matthew D |
CSO & Exec VP of Research |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$673 |
D/D |
455 |
4,809 |
|
- |
|
| Jenn Paul |
VP of Product Development |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$436 |
D/D |
295 |
2,207 |
|
- |
|
| Welch William J |
VP Sales & Marketing |
• – – |
2004-09-30 |
5 |
A |
$2.08 |
$541 |
D/D |
260 |
1,462 |
|
- |
|
| Sloan Gail A |
VP of Finance |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$390 |
D/D |
264 |
12,976 |
|
- |
|
| Heilbrunn Kenneth R |
VP of Clinical Development |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$670 |
D/D |
453 |
10,474 |
|
- |
|
| Reilly Teddi |
VP of Human Resources |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$2,053 |
D/D |
1,388 |
20,434 |
|
- |
|
| Bennett Bruce K Jr |
VP of Manufacturing |
• – – |
2004-09-30 |
5 |
A |
$1.48 |
$464 |
D/D |
314 |
37,110 |
|
- |
|
| Wiseman Andrew |
Sen Dir Investor Relations |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$456 |
D/D |
308 |
17,365 |
|
- |
|
| Linnik Matthew D |
CSO & Exec VP of Research |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$797 |
D/D |
539 |
4,354 |
|
- |
|
| Jenn Paul |
VP of Product Development |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$516 |
D/D |
349 |
1,912 |
|
- |
|
| Welch William J |
VP Sales & Marketing |
• – – |
2004-06-30 |
5 |
A |
$2.07 |
$638 |
D/D |
309 |
1,202 |
|
- |
|
| Sloan Gail A |
VP of Finance |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$464 |
D/D |
314 |
12,712 |
|
- |
|
| Heilbrunn Kenneth R |
VP of Clinical Development |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$793 |
D/D |
536 |
10,021 |
|
- |
|
| Reilly Teddi |
VP of Human Resources |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$2,427 |
D/D |
1,641 |
19,046 |
|
- |
|
| Bennett Bruce K Jr |
VP of Manufacturing |
• – – |
2004-06-30 |
5 |
A |
$1.48 |
$550 |
D/D |
372 |
36,796 |
|
- |
|
| Wiseman Andrew |
Sen Dir Investor Relations |
• – – |
2004-06-18 |
5 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
6,045 |
|
- |
|
| Wiseman Andrew |
Sen Dir Investor Relations |
• – – |
2004-06-09 |
5 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
7,045 |
|
- |
|
567 Records found
|
|
Page 21 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
